Cargando…

Cost-effectiveness of janus kinase inhibitors for rheumatoid arthritis: A systematic review and meta-analysis of cost-utility studies

Introduction: Janus kinase inhibitors (JAK-i), a class of targeted synthetic disease-modifying antirheumatic drugs (tDMARDs), are suggested as second or third-line therapies in rheumatoid arthritis (RA). Synthesized cost-effective evidence would aid in informed decision-making given the similar clin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kumar, S. Sajith, Haridoss, Madhumitha, Venkataraman, Krishnamurthy, Bagepally, Bhavani Shankara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792993/ https://www.ncbi.nlm.nih.gov/pubmed/36582538 http://dx.doi.org/10.3389/fphar.2022.1090361

Ejemplares similares

Household catastrophic health expenditures for rheumatoid arthritis: a single centre study from South India
por: Bagepally, Bhavani Shankara, et al.
Publicado: (2023)

Association Between Janus Kinase Inhibitors Therapy and Mental Health Outcome in Rheumatoid Arthritis: A Systematic Review and Meta-analysis
por: Shamail, Ghazala M. H., et al.
Publicado: (2021)

Cost-effectiveness of surgical mask, N-95 respirator, hand-hygiene and surgical mask with hand hygiene in the prevention of COVID-19: Cost effectiveness analysis from Indian context
por: Bagepally, Bhavani Shankara, et al.
Publicado: (2021)

Is COVID-19 severity associated with telomere length? A systematic review and meta-analysis
por: Haridoss, Madhumitha, et al.
Publicado: (2023)

Cost-effectiveness of Ezetimibe plus statin lipid-lowering therapy: A systematic review and meta-analysis of cost-utility studies
por: Sasidharan, Akhil, et al.
Publicado: (2022)

Incremental net benefit of cholecystectomy compared with alternative treatments in people with gallstones or cholecystitis: a systematic review and meta-analysis of cost–utility studies
por: Bagepally, Bhavani Shankara, et al.
Publicado: (2022)

Systematic review and meta-analysis of gallstone disease treatment outcomes in early cholecystectomy versus conservative management/delayed cholecystectomy
por: Bagepally, Bhavani Shankara, et al.
Publicado: (2021)

Cardiovascular safety of Janus kinase inhibitors in patients with rheumatoid arthritis: systematic review and network meta-analysis
por: Wei, Qige, et al.
Publicado: (2023)

Is State-Wise Healthcare Budget Allocation Consistent With the Disease Burden in India? A Quinquennial Account (2015–2019)
por: Bagepally, Bhavani Shankara, et al.
Publicado: (2022)

Air pollution attributed disease burden and economic growth in India: Estimating trends and inequality between states
por: S, Sajith Kumar, et al.
Publicado: (2022)

A perspective on trends in air pollution attributed disease burden in India-Authors' reply
por: Sajith Kumar, S, et al.
Publicado: (2022)

Efficacy and safety of baricitinib and tocilizumab in hospitalized patients with COVID-19: A comparison using systematic review and meta-analysis
por: Cherian, Jerin Jose, et al.
Publicado: (2022)

Incremental Net Monetary Benefit of Bariatric Surgery: Systematic Review and Meta-Analysis of Cost-Effectiveness Evidences
por: Noparatayaporn, Prapaporn, et al.
Publicado: (2021)

Potential Adverse Events Reported With the Janus Kinase Inhibitors Approved for the Treatment of Rheumatoid Arthritis Using Spontaneous Reports and Online Patient Reviews
por: Song, Yun-Kyoung, et al.
Publicado: (2022)

Cost-Utility Analysis of Dapagliflozin Compared to Sulfonylureas for Type 2 Diabetes as Second-Line Treatment in Indian Healthcare Payer’s Perspective
por: Bagepally, Bhavani Shankara, et al.
Publicado: (2021)

Oral Janus Kinase Inhibitor for the Treatment of Rheumatoid Arthritis: Tofacitinib
por: Ni, Han, et al.
Publicado: (2013)

Cardiovascular risk of Janus kinase inhibitors compared with biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis without underlying cardiovascular diseases: a nationwide cohort study
por: Song, Yun-Kyoung, et al.
Publicado: (2023)

Quality of Life and Cost Study of Rheumatoid Arthritis Therapy With Biological Medicines
por: Boyadzieva, Vladimira V., et al.
Publicado: (2018)

Risk of venous thromboembolism with janus kinase inhibitors in inflammatory immune diseases: a systematic review and meta-analysis
por: Zhang, Juqi, et al.
Publicado: (2023)

Clinical Aspects of Janus Kinase (JAK) Inhibitors in the Cardiovascular System in Patients with Rheumatoid Arthritis
por: Kotyla, Przemysław J., et al.
Publicado: (2020)

Changes in the cholesterol profile of patients with rheumatoid arthritis treated with biologics or Janus kinase inhibitors
por: Koh, Jung Hee, et al.
Publicado: (2023)

Janus Kinase Inhibitors in Rheumatoid Arthritis: An Update on the Efficacy and Safety of Tofacitinib, Baricitinib and Upadacitinib
por: Harrington, Robert, et al.
Publicado: (2023)

Drug Retention Rates and the Safety of Janus Kinase Inhibitors in Elderly Patients with Rheumatoid Arthritis
por: Temmoku, Jumpei, et al.
Publicado: (2023)

Therapeutic implications of current Janus kinase inhibitors as anti-COVID agents: A review
por: Jain, Nem Kumar, et al.
Publicado: (2023)

Association between blood lead levels and markers of calcium homeostasis: a systematic review and meta-analysis
por: Upadhyay, Kuldip, et al.
Publicado: (2022)

Novel Potential Janus Kinase Inhibitors with Therapeutic Prospects in Rheumatoid Arthritis Addressed by In Silico Studies
por: Radu, Andrei-Flavius, et al.
Publicado: (2023)

Drug retention of biologics and Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study
por: Ebina, Kosuke, et al.
Publicado: (2023)

Drug Retention Rates of Janus Kinase Inhibitors in Rheumatoid Arthritis Patients with Therapy-Induced Lymphopenia
por: Temmoku, Jumpei, et al.
Publicado: (2023)

The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis
por: Kawalec, Paweł, et al.
Publicado: (2013)

Meta-analysis of economic evaluation studies: data harmonisation and methodological issues
por: Bagepally, Bhavani Shankara, et al.
Publicado: (2022)

Assessment of Bone Turnover Biomarkers in Lead-Battery Workers with Long-Term Exposure to Lead
por: Ravibabu, Kalahasthi, et al.
Publicado: (2020)

Association of Musculoskeletal Disorders and Inflammation Markers in Workers Exposed to Lead (Pb) from Pb-battery Manufacturing plant
por: Ravibabu, Kalahasthi, et al.
Publicado: (2019)

Association between Musculoskeletal Pain and Bone Turnover Markers in Long-Term Pb-Exposed Workers
por: Kalahasthi, Ravibabu, et al.
Publicado: (2021)

Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme
por: Curtis, Jeffrey R, et al.
Publicado: (2016)

Tofacitinib, an Oral Janus Kinase Inhibitor: Pooled Efficacy and Safety Analyses in an Australian Rheumatoid Arthritis Population
por: Hall, Stephen, et al.
Publicado: (2018)

Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition
por: Dowty, Martin E., et al.
Publicado: (2019)

Risk of venous thromboembolism associated with Janus kinase inhibitors for rheumatoid arthritis: case presentation and literature review
por: Mori, Shunsuke, et al.
Publicado: (2021)

Factors affecting drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study
por: Ebina, Kosuke, et al.
Publicado: (2022)

Janus kinase inhibitors effectively improve pain across different disease activity states in rheumatoid arthritis
por: De Stefano, Ludovico, et al.
Publicado: (2023)

Cost Effectiveness of TNF-α Inhibitors in Rheumatoid Arthritis
por: Said, Cynthia, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_60h9ktaasn2k50plnsgkbrkdph